Senior or Executive Director, GI Medical Strategy
About the job
- An advanced degree (MD, PhD, or PharmD) in a medical or science specialty is preferred; significant medical-field experience may be considered in lieu of an advanced degree.
- At least 8 years of related experience at a pharmaceutical company in a Medical Affairs or clinical development role.
- Significant understanding and experience in gastrointestinal cancers, including evolving disease, treatment, and thought-leader landscapes.
- Strong scientific acumen to communicate with key internal and external stakeholders.
- A firm understanding of the strategy and processes involved in both the non-clinical and clinical aspects of drug development.
- Experience managing budgets and vendor partnerships.
- A demonstrated understanding of the legal and compliance environment of the pharmaceutical industry.
- Twenty to thirty-five percent domestic and international travel is required to attend key internal and external professional meetings.
- Serve as the strategic and tactical lead for gastrointestinal cancers in Medical Affairs.
- Coordinate across Medical Affairs, Research and Development, and other functions by developing and maintaining strategic plans and budgets.
- Partner with internal stakeholders to develop the overall gastrointestinal cancers medical strategy, clinical development plan, evidence-generation strategy, scientific narrative, and key opinion leader engagement strategy.
- Collaborate on and drive gastrointestinal cancers tactical planning.
- Manage execution of Medical Affairs activities, including publication development, insight-generation initiatives, medical communications, evidence generation, training, and early access.
- Serve as a subject-matter expert in gastrointestinal oncology, with an emphasis on precision therapeutics in pancreatic cancer.
- Assimilate emerging information into existing disease-state and competitive contexts.
- Develop and manage strategic relationships with gastrointestinal oncology thought leaders.
- Facilitate relationships with external societies, advocacy groups, and alliance partners.
- Lead Medical Affairs gastrointestinal oncology research studies, including Phase 4 company-sponsored research, registries, investigator-sponsored research, collaborative trials, meta-analyses, and retrospective studies.
- Provide scientific expertise on study design, rationale, and alignment to strategy.
- Perform all duties in accordance with the company’s core values, policies, and applicable regulations.
- Strong and timely oral and written communication skills, with the ability to build trust and respect among partners.
- Ability to lead with influence and vision and serve as a culture builder.
- Agility and flexibility when working across diverse therapeutic areas in a fast-paced, growth-stage biotechnology company.
- A proven track record of timely decision-making, prioritization, and a solution-oriented approach to addressing objectives.
- Demonstrated ability to achieve high-performance goals and meet deadlines in a fast-paced environment, collaborate effectively, and identify and implement creative solutions to complex problems.
- A strong learning orientation, curiosity, and commitment to science and patients.
About the company
Erasca is a clinical-stage precision oncology company focused on stopping the RAS/MAPK signaling pathway, a major driver in many cancers. Its products aim to block this pathway across multiple modalities to treat a wide range of tumors that rely on RAS/MAPK signaling. The company distinguishes itself by pursuing a comprehensive shutdown of the pathway through diverse therapeutic approaches, targeting cancer patients worldwide and seeking to bring multiple therapeutic programs to approval and commercialization. Its ultimate goal is to eradicate cancer and improve outcomes for millions of patients affected by RAS/MAPK-driven tumors.
Company Size
51-200
Company Stage
IPO
Headquarters
San Diego, California
Founded
2018
Get referred to Erasca
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 15, 2026 Erasca raised $632.5 million, funding three potentially registration-enabling trials.
- July 13, 2026 data showed ongoing responses, no DLTs, and median RDI of 100%.
- Management plans 2027 lung and pancreatic pivotal studies, extending catalysts beyond 2026.
What critics are saying
- April 24, 2026 RevMed accused ERAS-0015 of patent infringement and trade secret misappropriation.
- April 27, 2026 disclosed a patient death, triggering a 48% share collapse and litigation.
- ERAS-0015's franchise concentration creates an existential failure if later trials disappoint or IP injunctions block launch.
What makes Erasca unique
- ERAS-0015 targets pan-RAS signaling; July 13, 2026 data showed 57% uORR in KRAS G12X PDAC.
- August 24, 2026 FDA Fast Track for metastatic pancreatic adenocarcinoma validates Erasca's lead program.
- Charles Fuchs joined August 10, 2026, adding GI oncology drug-development depth to R&D.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Life Insurance
Pet Insurance
Paid Vacation
Paid Holidays
Paid Sick Leave
401(k) Retirement Plan
Company Equity
Employee Stock Purchase Plan
Growth & Insights and Company News
6 month growth
0%1 year growth
-1%2 year growth
-1%Johnson Fistel, PLLP investigates claims on behalf of long-term shareholders of Erasca, Inc. (ERAS), DICK'S Sporting Goods, Inc. (DKS), Corcept Therapeutics Incorporated (CORT), and Charter Communications, Inc. (CHTR). SAN DIEGO, Oct. 09, 2026 (GLOBE NEWSWIRE) - Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Erasca, Inc. (NASDAQ: ERAS), DICK'S Sporting Goods, Inc. (NYSE: DKS), Corcept Therapeutics Incorporated (NASDAQ: CORT), and Charter Communications, Inc. (NASDAQ: CHTR) against certain of their officers and directors for alleged breaches of fiduciary duty. Shareholders who purchased shares before the dates listed below and have continuously held those shares may have standing to seek corporate governance reforms and the return of funds to the company. For a named plaintiff, the firm may also seek a reasonable incentive award, subject to court approval. Representation is on a contingency-fee basis, with no legal fees or expenses payable by participating shareholders. Erasca, Inc. (NASDAQ: ERAS) If you purchased Erasca shares before January 14, 2025, and have continuously held those shares, you may have standing to seek corporate governance reforms at Erasca, including improvements to clinical-development oversight, intellectual-property risk management, disclosure practices, and executive accountability. To learn more, visit https://www.johnsonfistel.com/investigations/erasca/ or contact Johnson Fistel, PLLP at [email protected] or (619) 814-4471. There is no cost or obligation. Complaint Allegations A previously filed securities complaint concerns Erasca's disclosures about its drug candidate ERAS-0015. According to the complaint, Erasca disclosed on April 27, 2026, that Revolution Medicines had sent a letter raising patent-infringement and trade-secret allegations and challenging public comparisons between ERAS-0015 and Revolution Medicines' RMC-6236. The complaint also addresses subsequent preliminary clinical results, a reported patient death, and Erasca's acknowledgment that comparisons with other drug candidates relied on inherently limited cross-study analyses rather than direct, head-to-head trials. DICK'S Sporting Goods, Inc. (NYSE: DKS) If you purchased DICK'S Sporting Goods shares before May 25, 2022, and have continuously held those shares, you may have standing to seek corporate governance reforms at DICK'S, including improvements to inventory management, demand forecasting, disclosure controls, and executive oversight. To learn more, visit https://www.johnsonfistel.com/investigations/dicks-sporting-goods/ or contact Johnson Fistel, PLLP at [email protected] or (619) 814-4471. There is no cost or obligation. Complaint Allegations A previously filed securities class action complaint alleges that DICK'S and certain executives misrepresented demand and inventory conditions in the Company's outdoor segment. Specifically, demand allegedly weakened more rapidly than disclosed, leaving the Company with excess merchandise. The complaint further alleges that operational improvements promoted by defendants were insufficient to prevent inventory liquidation from reducing profitability. Consequently, defendants' favorable statements about the Company's business and outlook allegedly lacked a reasonable basis. Corcept Therapeutics Incorporated (NASDAQ: CORT) If you purchased Corcept shares before October 31, 2024, and have continuously held those shares, you may have standing to seek corporate governance reforms at Corcept, including improvements to regulatory-risk oversight, clinical-data disclosures, internal controls, and executive accountability. To learn more, visit https://www.johnsonfistel.com/investigations/corcept-therapeutics-inc-2/or contact Johnson Fistel, PLLP at [email protected] or (619) 814-4471. There is no cost or obligation. Complaint Allegations A previously filed securities class action complaint alleges that Corcept and certain executives misled investors about the likelihood of FDA approval of relacorilant for patients with hypercortisolism. Defendants allegedly expressed confidence in the application while failing to disclose repeated FDA concerns about whether the supporting clinical evidence was adequate. On December 31, 2025, Corcept announced that the FDA had issued a Complete Response Letter requiring additional evidence of effectiveness before it could reach a favorable benefit-risk assessment. The complaint alleges that this disclosure revealed previously undisclosed regulatory risks. Charter Communications, Inc. (NASDAQ: CHTR) If you purchased Charter shares before July 26, 2024, and have continuously held those shares, you may have standing to seek corporate governance reforms at Charter, including improvements to subscriber-trend reporting, financial forecasting, disclosure controls, and executive oversight. To learn more, visit https://www.johnsonfistel.com/investigations/charter-communications-inc-nasdaq-chtr/ or contact Johnson Fistel, PLLP at [email protected] or (619) 814-4471. There is no cost or obligation. Complaint Allegations A previously filed securities class action complaint alleges that Charter and certain executives misled investors about the business consequences of the termination of the Federal Communications Commission's Affordable Connectivity Program ("ACP"). According to the complaint, defendants understated the resulting pressure on Internet subscriber trends, revenue, and sustainable earnings growth. The complaint further alleges that these conditions undermined the basis for defendants' optimistic statements about operations and long-term EBITDA growth, with subsequent disappointing results allegedly exposing the earlier misrepresentations. About Johnson Fistel, PLLP | Top Law Firm, Securities Fraud, Investors Rights: Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. We also extend our services to foreign investors who have purchased on U.S. exchanges. For more information about the firm and how we may be able to help you recover your losses, please visit https://www.johnsonfistel.com. Achievements: In 2024, Johnson Fistel was ranked in the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. The firm has recovered approximately $90,725,000 for aggrieved clients in cases where it served as lead or co-lead counsel, marking the eighth time it has been recognized among the top U.S. plaintiffs' securities law firms. Johnson Fistel, PLLP 501 W. Broadway, Suite 800 San Diego, CA 92101 James Baker, Investor Relations, or Frank J. Johnson, Esq. (619) 814-4471 [email protected] or [email protected]
Erasca, Inc. (NASDAQ:ERAS) stock has consensus target price of $22.09. October 3, 2026 Key points. * Analysts maintain a "Moderate Buy" consensus on Erasca, with eight buy, two hold, and one sell rating among 11 brokerages. The average 12-month price target is $22.09, above the stock's reported $14.74 opening price. * Erasca shares were up 1.1%, with a market capitalization of approximately $5.16 billion and a 52-week range of $2.11 to $24.28. The company reported quarterly EPS of negative $0.14, missing the consensus estimate of negative $0.11. * Institutional investors and hedge funds own approximately 67.78% of Erasca's stock. The clinical-stage biopharmaceutical company is developing precision cancer medicines targeting abnormalities in the RAS/MAPK signaling pathway. * Five stocks to consider instead of Erasca. Erasca, Inc. (NASDAQ:ERAS - Get Free Report) has received an average recommendation of "Moderate Buy" from the eleven brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $22.09. A number of analysts have weighed in on ERAS shares. HC Wainwright increased their price target on Erasca from $18.00 to $22.00 and gave the stock a "buy" rating in a report on Wednesday, August 12th. Bank of America lifted their target price on Erasca from $18.00 to $20.00 and gave the stock a "neutral" rating in a report on Friday, August 14th. Morgan Stanley lifted their price objective on shares of Erasca from $12.00 to $21.00 and gave the company an "equal weight" rating in a research note on Monday, July 20th. Guggenheim increased their target price on shares of Erasca from $20.00 to $21.00 and gave the stock a "buy" rating in a research note on Thursday, August 13th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Erasca in a report on Tuesday, September 8th. Erasca stock up 1.1%. Shares of Erasca stock opened at $14.74 on Friday. The stock has a market cap of $5.16 billion, a price-to-earnings ratio of -15.52 and a beta of 0.61. Erasca has a twelve month low of $2.11 and a twelve month high of $24.28. The company's fifty day moving average is $16.85 and its 200 day moving average is $15.87. Erasca (NASDAQ:ERAS - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.03). As a group, equities analysts anticipate that Erasca will post -0.49 earnings per share for the current fiscal year. Institutional inflows and outflows. A number of institutional investors have recently added to or reduced their stakes in the company. Wealthcare Advisory Partners LLC raised its holdings in Erasca by 5.0% during the second quarter. Wealthcare Advisory Partners LLC now owns 15,924 shares of the company's stock worth $292,000 after buying an additional 756 shares during the last quarter. Abel Hall LLC grew its holdings in shares of Erasca by 8.1% during the first quarter. Abel Hall LLC now owns 16,947 shares of the company's stock valued at $274,000 after buying an additional 1,265 shares during the last quarter. Nykredit A S bought a new stake in shares of Erasca during the second quarter worth about $29,000. Allworth Financial LP acquired a new stake in shares of Erasca in the 2nd quarter worth about $34,000. Finally, EverSource Wealth Advisors LLC lifted its position in Erasca by 77.8% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,249 shares of the company's stock valued at $69,000 after acquiring an additional 1,859 shares in the last quarter. 67.78% of the stock is owned by institutional investors and hedge funds. Erasca company profile. Erasca, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancers driven by abnormal signaling in the RAS/MAPK pathway. The company's research and development activities target tumors with RAS mutations or other alterations that can promote cancer growth and resistance to treatment. Discover more All Access membership Stock research tools Erasca's pipeline has included naporafenib, an investigational pan-RAF inhibitor designed to block signaling downstream of RAF proteins, as well as other targeted therapies aimed at genetically defined cancer populations. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Erasca, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Erasca wasn't on the list. While Erasca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you'll find 7 stocks that could play a major role in the next tech-driven market boom. Continue following MarketBeat
The US Food and Drug Administration has granted Fast Track Designation to Erasca's ERAS-0015 for patients with metastatic pancreatic adenocarcinoma. The designation enables more frequent regulatory contact and potential accelerated approval pathways. ERAS-0015, an oral pan-RAS molecular glue, showed a 57% response rate in a Phase 1 trial of patients with second-line or later KRAS G12X pancreatic cancer. All responders remained on treatment as of the May data cutoff. Erasca plans to launch three pivotal trials, targeting a registration-enabling lung cancer study for the first half of 2027. The company raised approximately $891.3 million through two offerings in 2026, ending June with $384.3 million in cash. Second-quarter net loss widened to $44.1 million from $33.9 million year-over-year.
Erasca, a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, has appointed Charles S. Fuchs as president of research and development. Dr Fuchs brings over 30 years of oncology leadership experience, having most recently served as chief medical officer at Tubulis, which was acquired by Gilead. Previously, he held senior positions at Genentech and Roche, where he led the development of several approved therapies. He also served as director of Yale Cancer Center and held leadership roles at Dana-Farber Cancer Institute and Harvard Medical School. Erasca's CEO Jonathan Lim highlighted Dr Fuchs's expertise in gastrointestinal cancers and drug development. The company develops therapies targeting the RAS/MAPK pathway for cancer treatment.
Erasca faces class action lawsuit, stock takes hit. Lawsuits and stocks: A volatile cocktail. You ever see a stock drop clear off the edge and into the abyss? That's Erasca, Inc. (NASDAQ: ERAS) for you. They're on the chopping block for allegedly misleading investors over their oncology darling, ERAS-0015. And buddy, when you mess with investors' trust, it's like throwing gasoline on a bonfire - stocks go up in flames. Unraveling the allegations. Hagens Berman, those crusaders with a penchant for sniffing out corporate drama, have zeroed in on Erasca. The lawsuit claims Erasca's execs dressed up ERAS-0015 as a knight in shiny armor against cancer. Trouble is, this knight might have been rusty as all get out. Investors Hangout, LLC is talking questionable study comparisons and a hush-hush attitude about potential IP battles with Revolution Medicines. Oh, and glossing over safety mishaps? Seems like business as usual till it isn't, especially when a patient loses their life. The cold, hard crash. If you thought April showers brought May flowers, think again. Late April brought disclosures that socked it to Erasca's share price, and hard. First, they got slapped with a challenge over IP from Revolution Medicines. Then, they had to come clean about grim clinical data tied to ERAS-0015 - stuff no one wanted to hear but needed to know. A double whammy that yanked over $2.8 billion out of the market cap. Makes you wonder who's steering that ship. "It's a mess when investor confidence goes belly up," one market hawk commented, likely shaking their head at the numbers." What lies ahead for Erasca? Investors who forked over cash between January 2025 and April 2026 are now sizing up their options to dish back some of what they lost. With the August 10, 2026 deadline looming to hop on the lead plaintiff wagon, the clock's ticking fast. For those with a front-row seat to this corporate opera, there's potential gold in those hills if you can provide juicy insider info via the SEC Whistleblower program. Success there might put some change back in your pocket to the tune of 30% of whatever the SEC collects. Not too shabby for case-building, is it? Investor's troubles: more than meets the eye. Here's where things get sticky. Class actions don't often provide quick resolutions, and shareholders are left trying to see past the haze. Erasca might be tenacious, but playing footsie with facts has a way of coming back to haunt. Navigating the chaotic waters. Discerning whether Erasca can crawl back from this tailspin is a lesson in grit and transparency. It's a tightrope walk between maintaining investor trust and keeping those lawsuits at bay. The fallout, coupled with stock market waves, makes this a real head-scratcher for any savvy investor. Class action resolutions could take a spell, so keep those nerves in check and eyes peeled for how this tale unfolds. If all this sounds eerily familiar, that's because Investors Hangout, LLC has seen this song and dance before: companies puffing up their feathers only to find themselves plucked bare when the truths are unveiled. But these stories really hold a magnifying glass to investor reliance on corporate integrity. So, there you have it. Today's lesson in 'what goes around, comes around' comes wrapped in legal battles and significant investment losses. Makes you rethink how you weigh those corporate promises, doesn't it?